The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

By Paul Markovich

Blame the middlemen

Humira's continued dominance after losing patent protection is one example of why the system for distributing drugs is broken.

More than 300,000 Americans use a medication called Humira. Most of them are paying far too much for it.

Humira, the brand name of AbbVie's (ABBV) adalimumab, is prescribed to treat inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and Crohn's disease. The Food and Drug Administration approved Humira at the end of 2002, and it quickly became a blockbuster drug.

For 20 years, while AbbVie had a patent, Humira dominated the market, generating nearly $200 billion in revenue. In 2023, doctors in the U.S. wrote nearly 4 million prescriptions at an average list price per prescription of $5,221. In July of that year, Humira's patent expired. Nine biosimilars - which are FDA-approved drugs with the same safety, effectiveness and treatment benefits as the original drug - flooded the market at substantially lower prices.

If traditional market economics were in play, patients would have immediately switched to the lower-priced alternatives, forcing AbbVie to lower Humira's price or face losing its dominant market share in the U.S.

Unfortunately, that's not what happened. In 2025, two years after its patent expired, and at a $7,000 list price, Humira still had 72% of the market. The reason? The system for distributing drugs is broken.

In the current system, everyone - from pharmacy-benefit managers to some doctors and hospitals - makes more money when a higher volume of more expensive drugs is sold, regardless of whether those medications are the best choice for the patient. Every link in the drug-distribution chain gets a commission, meaning the financial incentives work against directing patients to less expensive but equally effective medicines.

Humira is just one example, but it's a fascinating case study for understanding how healthcare costs have gotten so horribly out of control and what's needed to fix it.

The middlemen

To understand where the system breaks down, we must begin with PBMs - the middlemen hired by health plans to negotiate lower prices from drug manufacturers and manage prescription drug benefits for patients. Health plans hoped PBMs would create efficiencies. Instead, PBMs engage in profit-maximizing practices that are legal but shouldn't be.

Specifically, PBMs require drug manufacturers to pay fees and rebates tied to a drug's list price to secure placement on formularies. These are essentially kickbacks that drive the economic engine of PBMs. Sell more expensive drugs, collect bigger fees. In the case of Humira, by 2025, the list price was about $7,000 per month, but the manufacturer kicked back nearly $5,000 in fees and rebates to PBMs. So, the PBMs had every financial incentive to keep selling Humira rather than provide patients with a much less expensive biosimilar version of the medicine. Because the three largest PBMs control 80% of the market, drug manufacturers keep paying the fees.

Additionally, the three largest PBMs are owned by large health plans, which also own group purchasing organizations, specialty pharmacies, and in some cases retail pharmacies and physician practices. All these entities also receive payments tied to the list price of a drug, which means one corporate organization pockets the fees and commissions at every level, from manufacture to pickup. In some cases, the vertically integrated companies offer better reimbursement to the pharmacies they own.

It isn't just health insurance premiums that increase because of this system. The copay - the amount insured patients must pay out of their own pocket - is often tied to a drug's list price. In the case of Humira, that's $7,000 instead of the approximately $2,000 paid to the manufacturer. Delinking compensation for PBMs from list prices of prescription drugs would likely save Americans $95.4 billion.

We know the industry will not do this voluntarily. We've tried.

In 2023, my company, Blue Shield of California, partnered with CivicaScript, a nonprofit organization that develops and manufactures generic versions of high-cost medicines, to obtain a generic version of abiraterone acetate, a drug used to treat advanced prostate cancer. The chemically equivalent generic costs $160 per dose - a steep discount from the brand-name version at $3,000 a dose. When we approached our PBM about distributing the discounted version, the team refused, citing every flimsy excuse it could muster. It took months of pressure before our PBM relented and allowed us to distribute an identical drug at a fraction of the cost.

In 2024, Blue Shield created Pharmacy Care Reimagined to negotiate directly with drug companies to provide its members with better access to biosimilar medicines. The first agreement under this new model was for an FDA-approved biosimilar of Humira that allowed Blue Shield of California to provide the medicine to most of its commercial members with no money out of pocket.

Tough love

That's why the government needs to step in. We need federal legislation that prohibits PBMs and their affiliated companies from collecting fees based on drug prices, volume of drugs sold, or placement on a formulary. Providers and patients must know the net price of a drug and have copays tied to that price rather than the inflated list prices. That means any discounts offered by drug companies would benefit patients, not PBMs.

There is real momentum for these changes. California enacted major PBM reform last year with the adoption of Senate Bill 41, which went into effect Jan. 1. The law prohibits PBMs from engaging in spread pricing, requires them to pass 100% of drug companies' rebates and price concessions to the health plan or payer, and limits their compensation to a flat, disclosed administrative fee, among other things. These actions make pharmaceutical choices more transparent, affordable and fairer to patients.

Congress is also taking notice. On Feb. 4, the House passed PBM reform as part of a $1.2 trillion funding bill. The legislation imposes transparency requirements and prohibits PBMs from linking their compensation to drug list prices in Medicare Part D.

These are good steps forward, but we must do more. If we want to build a healthcare system that is accessible, affordable and worthy of our friends and family, we need to band together - consumers, patients, employers and every level of government - to make it clear that the status quo is unacceptable. Fixing our healthcare system won't be easy, but PBM reform is a great place to start.

Paul Markovich is president and CEO of Ascendiun, a nonprofit parent company of Blue Shield of California, Blue Shield Promise Health Plan, Altais and Stellarus. He took over as CEO of Blue Shield of California in 2013.

-Paul Markovich

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

04-08-26 0709ET

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center